Altimmune (ALT) plans New Jersey HQ move with 5-year lease

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Altimmune, Inc. reported that it plans to relocate its corporate headquarters from Gaithersburg, Maryland to Morristown, New Jersey later this year. The company describes the new area as a strong biopharmaceutical hub that it expects will support recruiting top-tier talent within its hybrid work model.

Altimmune has signed an office lease for the New Jersey headquarters, under which it will pay approximately $300,000 in rent annually over a 5-year lease term. The company states that the headquarters move is expected to help achieve cost efficiencies over the long term, while it continues its growth as a late-stage development company.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Figures

Annual headquarters rent: $300,000 per year Lease term: 5 years

2 metrics

Annual headquarters rent $300,000 per year Office lease for Morristown, New Jersey headquarters

Lease term 5 years New corporate headquarters office lease

Key Terms

late-stage development company, hybrid business model, forward-looking statements, Private Securities Litigation Reform Act of 1995, +1 more

5 terms

late-stage development company financial

"as the Company continues its growth as a late-stage development company"

hybrid business model financial

"support the Company’s ability to attract top-tier talent in its hybrid business model"

forward-looking statements regulatory

"contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

Private Securities Litigation Reform Act of 1995 regulatory

"within the meaning of the Private Securities Litigation Reform Act of 1995, as amended"

Risk Factors regulatory

"described in greater detail in the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K"

Risk factors are elements or conditions that could cause an investment's value to decrease or lead to potential losses. They are like warning signs or obstacles that can affect the success of an investment, making it uncertain or more unpredictable. Recognizing risk factors helps investors understand the possible challenges and make more informed decisions.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

06/16/2026 - 04:05 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 16, 2026

ALTIMMUNE, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-32587	20-2726770
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

910 Clopper Road, Suite 201S Gaithersburg, Maryland		20878
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number including area code: (240) 654-1450

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value $0.0001 per share	ALT	The NASDAQ Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01 Other Events.

On June 16, 2026, Altimmune, Inc. (the “Company”) announced plans to relocate its corporate headquarters from Gaithersburg, Maryland to Morristown, New Jersey later this year. The new headquarters is in a geography with a strong presence of biopharmaceutical companies, which is expected to support the Company’s ability to attract top-tier talent in its hybrid business model, as the Company continues its growth as a late-stage development company.

The Company has entered into an office lease agreement for the New Jersey headquarters where the Company will make rent payments of approximately $300,000 annually for the 5-year lease term. The move of the headquarters is expected to help the company achieve cost efficiencies over the long term.

Cautionary Note Regarding Forward Looking Statements

This Current Report on Form 8-K and certain of the materials filed herewith contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the Offering and anticipated closing, and expectations regarding our cash runway, use of capital, expenses and other future financial results. The words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “expect,” “estimate,” “seek,” “predict,” “future,” “project,” “potential,” “continue,” “target” and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements, such as those related to the anticipated plan to relocate the Company’s headquarters, the anticipated timing of the relocation, the potential of the new location to assist in attracting talent, the continued growth of the company and any potential cost efficiencies created by the move, are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this Current Report on Form 8-K. These statements are based on management's current expectations and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent the Company’s views only as of today and should not be relied upon as representing its views as of any subsequent date. The Company explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ALTIMMUNE, INC.

	By:	/s/ Gregory Weaver
		Name: Gregory Weaver
		Title: Chief Financial Officer

Dated: June 16, 2026

Source: View Original Filing on SEC EDGAR

FAQ

What did Altimmune (ALT) announce in its latest 8-K filing?

Altimmune announced plans to move its corporate headquarters from Gaithersburg, Maryland to Morristown, New Jersey later this year. The company expects the new biopharmaceutical hub location to support talent attraction and long-term cost efficiencies as it grows as a late-stage development company.

Where is Altimmune (ALT) relocating its corporate headquarters?

Altimmune plans to relocate its corporate headquarters to Morristown, New Jersey. The company highlights the area’s strong biopharmaceutical presence, which it believes will help attract top-tier talent for its hybrid work model as it continues developing its late-stage pipeline.

What are the lease terms for Altimmune’s new New Jersey headquarters?

Altimmune entered an office lease for its Morristown, New Jersey headquarters with rent of approximately $300,000 annually. The lease term is five years, providing a multiyear base for the company’s operations as it advances as a late-stage development company.

Why does Altimmune (ALT) believe the headquarters move will help the business?

Altimmune expects the move to Morristown, New Jersey to support attracting top-tier biopharmaceutical talent and to create cost efficiencies over the long term. The company links the relocation to its continued growth trajectory as a late-stage development organization.

Does Altimmune’s 8-K filing include forward-looking statement warnings?

Yes. The filing includes an extensive forward-looking statements section referencing the Private Securities Litigation Reform Act of 1995, highlighting that expectations about the relocation, timing, talent attraction, growth, and cost efficiencies are subject to risks described in its Form 10-K and later filings.

Filing Exhibits & Attachments

3 documents